| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55527
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-80
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55533
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-645
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6093 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4748
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6933
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-385 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-69
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32 |
| filingDate |
2019-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2022-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2022513927-A |
| titleOfInvention |
Phagocytosable particles for use in the treatment or prevention of cancer |
| abstract |
The present invention provides phagocytic particles for use in the treatment or prevention of a subject's cancer, the phagocytic particles comprising a core and a neoantigenic construct strongly associated with the core. The sex construct comprises a neoepitope peptide having an amino acid sequence corresponding to the amino acid sequence of some of the proteins or peptides known or suspected to be expressed by the cancer cells of interest, with some of the proteins or peptides It has at least one somatic cell mutant amino acid. The invention also relates to an injectable pharmaceutical composition for use in the treatment or prevention of cancer. [Selection diagram] Fig. 1 |
| priorityDate |
2018-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |